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Marcie Tomblyn,1 Jo-Anne H. Young,2 Michael D. Haagenson,3 John P. Klein,3,4
Elizabeth A. Trachtenberg,5 Jan Storek,6 Stephen R. Spellman,3 Sarah Cooley,2
Jeffrey S. Miller,2 Daniel J. Weisdorf,2 on behalf of the CIBMTR Infection
and Immune Reconstitution Working CommitteeInfectious complications following allogeneic hematopoietic cell transplantation (HCT) from unrelated do-
nors (URD) result in significant morbidity. We hypothesized that recipients of a URD with an activating nat-
ural killer cell immunoglobulin-like receptor (KIR) (B/x) genotype would have decreased infectious
complications because of enhanced natural killer (NK) cell function. We compared the infectious complica-
tions in 116 recipients of a graft from a donor with an A/A KIR (n 5 44) genotype and a B/x KIR (n 5 72)
genotype. All recipients participated in the prospective National Marrow Donor Program infection project
collecting infection data from conditioning until 6 months posttransplant. The cohort with a B/x donor had
fewer initial bacterial infections by day 180 (A/A: 86%; 95% confidence interval [CI], 75-95; B/x: 68%; 95% CI,
57-78; P 5 .02). There was no difference in the incidence of viral or fungal infections. When accounting for
multiple infections, fewer bacterial infections were seen in the B/x cohort (A/A: 3.55/patient; B/x: 2.63/pa-
tient; P 5 .09). During the study period, only 19 patients had no infections; of these, 15 had received cells
from a B/x KIR donor. The role of donor KIR genotype on infection complications is intriguing and warrants
further investigation.
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Infections remain a common complication follow-
ing allogeneic hematopoietic cell transplantation
(HCT). In fact, almost 20% of recipients of hemato-
poietic cell grafts from unrelated donors (URD) report
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6/j.bbmt.2010.02.024killer (NK) cells, a subset of lymphocytes, act as cyto-
toxic effectors and/or cytokine producers and regula-
tors, engaging with a wide range of immunologic
effector cells to control the immune response. NK ac-
tivity is controlled by several families of cell surface in-
hibitory and/or stimulatory receptors including the
killer immunoglobulin-like receptors (KIR); inhibi-
tory KIR use HLA class I as their cognate ligands
[2]. KIR are genetically diverse, but can be broadly
categorized into 2 haplotypes [3]. The predominately
inhibitory haplotype ‘‘A,’’ has at most only a single ac-
tivating gene, KIR2DS4, although some A haplotypes
lack even this stimulatory gene [4,5]. Conversely, the
B haplotype has, in addition to KIR2DS4, which is
found in nearly all individuals, at least 1 additional
activating gene (eg, KIR2DS2, KIRDS3, KIRDS5,
KIR3DS1). An activating KIR genotype must have at
least 1 B haplotype, either as homozygous B/B or
heterozygous B/A (noted as B/x). In a Caucasian
population, it is expected that approximately two-
thirds of people will have an activating KIR genotype
[6,7].
An individual’s KIR genotype may alter their
response to specific infections. For example,1155
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KIR3DS1 in concert with HLA-BW4 demonstrate de-
layed progression to AIDS [8-10]. Furthermore,
clearance of chronic hepatitis B and C may be in part
regulated by the KIR genotype [4,11,12].
Following allogeneic transplantation, NK cells re-
cover most quickly though their specific contribution
to either favorable or adverse post-HCT outcomes is
uncertain [13]. In addition, we recently reported that
the donor KIR genotype significantly improves post-
transplant survival in transplants for acute myeloge-
nous leukemia (AML) [14]. However, data examining
donor KIR and posttransplant infectious complica-
tions have been mixed and studied primarily following
allogeneic sibling HCT [15,16].
We hypothesized that, following an URD alloge-
neic HCT, recipients of cells from donors with the ac-
tivating KIR genotype (B/x) will have fewer infections.
Therefore, we designed a study to analyze infectious
complications in relation to donor KIR genotypes.PATIENTS MATERIALS AND METHODS
Patients
The National Marrow Donor Program (NMDP)
conducted a project to assess infectious complications
following allogeneic URD HCT. All patients were
transplanted in 2002. A total of 211 recipients at 27
transplant centers were enrolled. All data were pro-
spectively collected and extensively audited to confirm
accuracy of the infectious complications reported. A
subset of recipients (n5 116) had DNA samples avail-
able for donor KIR genotyping through the NMDP
Research Repository, and their infectious outcomes
are reported here. The KIR genotyping was performed
utilizing MALDI-TOF mass spectrometry [17].Infection Data
Prospective data regarding infectious complica-
tions as well as antimicrobial prophylaxis were col-
lected weekly from the start of conditioning through
day 90 following HCT and then every 2 weeks until
day 180. Infections were included in the specific mi-
crobial categories only when a culture was identified.
A subset of patients had clinical infectious syndromes
without a specific organism identified. but therapy
was initiated, such as for probable fungal infections.
Fevers of unknown origin or neutropenic fever
without an identified organism were excluded. Recur-
rent infection was based on intervals from the time of
first infection to the next reported episode of the
same infection. A recurrent bacterial infection was
one that followed a 7-day window of negative cultures
except for Clostridium difficile infection, which required
a 30-day culture-negative period. The following viralinfections were considered recurrent after 14 days: var-
icella zoster (VZV), adenovirus, enterovirus, influenza,
parainfluenza, and rhinovirus. However, a 60-day win-
dow was required to score recurrent cytomegalovirus
(CMV), herpes simplex virus (HSV), and polyomavirus
infections. CMV reactivation was determined by anti-
genemia or polymerase chain reaction (PCR)-positive
surveillance as defined by institutional guidelines and
subsequently resulted in an initiation or change of
anti-CMV therapy. Fungal infections with yeast or
Cryptococcus could be recurrent after a 14-day win-
dow, but molds (eg, Aspergillus, Fusarium, Mucor,
etc.) required a 90-day window.
Statistical Analysis
The primary objective of this study was to compare
infectious complications in HCT recipients with
donors having an A/A KIR genotype versus those
with B/x KIR genotype. Outcomes of interest included
infection density, defined as the number of infections
per patient days at risk; cumulative incidence of bacte-
rial, viral, fungal, and overall infectious complications
at day 180; incidence of grade II to IV acute graft-
versus-host disease (aGVHD) [18]; and the incidence
of chronic GVHD (cGVHD). In addition, we analyzed
treatment-related mortality (TRM) at day 100 and
overall survival (OS) at 1 year.
Patient-, infection-, and treatment-related factors
were compared between the 2 KIR genotype cohorts
using chi-square testing for categoric and Mann-
Whitney testing for continuous variables. Models
were fit for the infection density at day 180 by using
a stepwise Poisson regression model with an offset for
the patient’s on study time. Factors tested in the model
included, in addition to the KIR genotype, patient age,
stem cell source (bone marrow [BM] versus peripheral
blood [PB]), diagnosis, and disease status, HLA match-
ing as defined by Weisdorf et al. [19], and CMV seros-
tatus of donor and recipient. Because patients develop
multiple infections over the 6-month period of obser-
vation, modeling of variables in relation to infection
density were tested for both overall infection as well
as bacterial, fungal, and viral groupings. We also exam-
ined, using Cox regression models, the time to first
infection of a given type. Here we included aGVHD
as a time-dependent covariate. The probability of OS
was calculated using the Kaplan-Meier estimate and
the survival compared for each KIR genotype group
at 180 and 360 days using a stepwise pseudovalue
regression model [20].RESULTS
Patients
Forty-four (38%) patients received cells from a do-
nor witha KIR A/A genotype and 72 (62%) froma donor
Table 1. Characteristics of PatientsDefined by KIRGenotype
Donor KIR
Genotype A/A
N 5 44
Donor KIR
Genotype B/x
N 5 72
Variable N (%) N (%) P-Value
Recipient age, years
Median (range) 39 (2-67) 40 (1-66) .66
Donor Age, years
Median (range) 34 (21-59) 34 (19-56) .30
Male sex 25 (57) 44 (61) .65
Karnofsky prior to
transplant >90%
21 (57) 43 (68) .45
Disease .68
Acute leukemia/MDS 32 (73) 52 (72)
CML 4 (9) 6 (8)
Lymphoma 7 (16) 10 (14)
Nonmalignant disorders 1 (2) 4 (6)
HLA-A, -B, -C, and
-DRB1 matching
.43
Well matched 24 (54) 41 (57)
Partially matched 10 (23) 21 (29)
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graphic and transplant characteristics in each group
are shown in Table 1. Patient characteristics including
median age of patients, sex, and Karnofsky performance
status were similar. Nearly three-quarters of patients in
each cohort had acute myelogenous leukemia (AML) or
myelodysplastic syndrome (MDS). The median age of
the donors was similar between the 2 groups: A/A do-
nors, 34 years (range: 21-59 years); B/x donors, 34 years
(range: 19-56 years). The median time from diagnosis to
HCT was similar in the 2 cohorts at 11 months (range:
1-159 months) for A/A donor recipients and 14 months
(range: 0.6-157 months) for those receiving cells from
a B/x donor. The conditioning intensity was similar
between the 2 groups. The median follow-up of survi-
vors is 48 months for the A/A donor cohort (range:
27-52 months) and 47 months for the B/x donors (range:
28-53 months).Mismatched 10 (23) 10 (14)
Conditioning regimen .30
Myeloablative 33 (75) 40 (55)
Reduced intensity 8 (18) 22 (31)
Nonmyeloablative 3 (7) 9 (13)
Unknown 0 1 (1)
Donor/recipient sex match .53
Male/male 15 (34) 22 (31)
Male/female 9 (20) 18 (25)
Female/male 10 (23) 22 (31)
Female/female 10 (23) 10 (14)
Donor/recipient CMV match .51
Negative/negative 8 (18) 21 (29)
Negative/positive 16 (36) 27 (38)
Positive/negative 11 (25) 10 (14)
Positive/positive 8 (18) 13 (18)
Unknown 1 (2) 1 (1)
Graft type .97
Bone marrow 24 (55) 39 (54)
Peripheral blood stem cells 20 (45) 33 (46)
GVHD Prophylaxis .68
Cyclosporine ± other 11 (25) 22 (31)
Tacrolimus ± other 23 (52) 39 (54)
T cell depletion 7 (16) 9 (13)
Other 3 (7) 2 (3)
CML indicates chronic myelogenous leukemia; CMV, cytomegalovirus;
GVHD, graft-versus-host disease; MDS, myelodysplastic syndrome.Bacterial Infections
As expected, bacterial infections were the most
common type of infection in the first 180 days post-
transplant. For the entire cohort of patients, the
mean number of bacterial infections was 2.99 per pa-
tient in the first 180 days following HCT (Figure 1).
With an A/A donor versus a B/x donor, the mean num-
ber of bacterial infections was 3.55/patient versus 2.63/
patient, respectively (P5 .09). In the first 180 days, the
cumulative incidence of bacterial infections for A/A
donor HCT was 86% (95% confidence interval [CI],
75-95) compared to only 68% (95% CI, 57-78) for
B/x donor (P 5 .02; Figure 2).
Twenty-nine patients had no bacterial infections
(A/A: n5 6 [14%]; B/x: n5 23 [32%]), whereas the en-
tire cohort of patients experienced 253 episodes of bac-
terial infection during the study period. The
predominant bacterial infections were Staphylococcus
epidermidis, which accounted for 90 separate infectious
episodes. Other common bacterial infections included
Gram-negative bacteria accounting for 51 episodes
(20%), Enterococcus infections (45 episodes, 18%), and
Clostridium difficile (18 episodes, 7%).
Antibacterial prophylaxis data was captured from
weeks 5-24 of the study period. Nearly half the patients
did not receive any bacterial prophylaxis during this
time period. The predominant antibacterial utilized
was penicillin, which was given to 6 patients each in
the A/A and B/x cohort between 5 and 12 weeks
posttransplant, and 7 and 8 patients in the respective
cohorts from weeks 13 to 24.
The Poisson adjusted mean number of bacterial in-
fections is shown in Figure 3. Although not reaching
statistical significance, the ratio of the adjusted mean
number of bacterial infections in the A/A cohort was
higher (1.17; (95% CI, 0.90 to 1.52; P5 .23) compared
to recipients of a B/x donor (reference group rate).Factors associated with an increased risk of bacterial in-
fections are shown in Table 2. Greater HLA mismatch
was associated with more bacterial infections and,
while BM versus PB as a stem cell source was associated
with fewer bacterial infections, neither KIR genotype
nor other factors were found to be significant in the
Poisson regression model.
Viral Infections
The mean estimated number of viral infections in
the first 180 days posttransplant for the entire cohort
was 0.90 per patient (Figure 1). The density of viral
infection was similar. Recipients of an A/A donor
had a mean of 0.93 viral infections per patient versus
only 0.88 per patient per days at risk for a B/x donor
(P 5 .53). The cumulative incidence of viral infection
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Figure 1. Mean number of infections during the first 180 days following
HCT. The mean number of infections is shown as the infection density
defined as the number of infections per patient per days at risk and nor-
malized over the 180-day study period.
Figure 3. The adjusted relative infection density for a KIR A/A (dotted
bar) donor recipient compared to a KIR B/x (line) donor recipient dur-
ing the first 180 days. A value above 1.0 indicates a higher mean ratio of
infections in the KIR A/A cohort.
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40%; 95% CI, 29%-52%; P 5 .58).
More than half of all patients experienced no viral
infections during the study period (A/A: n5 24, 55%;
B/x: n5 43, 60%). As expected, the predominant viral
organism reported was CMV. There were 52 episodes
of CMV reactivation during the study with 27 of these
episodes occurring between weeks 5 and 12 following
HCT. Other viral organisms reported included
respiratory viruses (9 episodes) and HSV or VZV
(14 episodes). Antiviral prophylaxis post-HCT was
similar between the 2 groups and consisted of predom-
inantly either acyclovir or valacyclovir between day 0
and 4 weeks following HCT (A/A: n 5 38, 86%; B/x:
n 5 62, 85%). This was continued through 12 weeks
posttransplant in 59% of patients (A/A: n 5 26,
59%; B/x: n 5 42, 58%).
By Poisson regression analysis, the adjusted viral
infection density (Figure 3) found that recipients of
an A/A donor had a ratio of 1.09 compared to recipi-
ents of a B/x donor (95% CI, 0.68-1.75; P 5 .72).
Donor-recipient sex match was associated with
a higher ratio of viral infections in recipients of male
donors regardless of recipient sex and with male recip-Figure 2. The cumulative incidence of bacterial infections in recipients
of a KIR A/A genotype and a KIR B/x genotype unrelated donor graft.ients of female donors. Similarly, CMV serostatus was
also significant such that a CMV seronegative
recipient with a negative donor had a lower ratio of
mean number of infections (0.3; 95% CI, 0.10-0.92;
P 5 .04). Conversely, CMV seropositive recipients
with a seronegative donor had a ratio of 2.14
(95% CI, 1.03-4.40; P5 .04) compared to the baseline
group of seropositive donor and seropositive recipient.
No other factors were significant in determining risks
of viral infection.Fungal Infections
Fungal infections were uncommon during the
study period and included both yeast and mold infec-
tious episodes. Only 26 fungal infection episodes
were documented, with 9 in the A/A group and 17 in
the B/x group during the 180 days following HCT.
Six of these were mold infections; 5 in the B/x cohort.
Thirty-five patients in the A/A cohort and 54 patients
in the B/x cohort had no fungal infections. Infection
density analysis found that the mean estimated number
of fungal infections was only 0.45 per patient
(Figure 1). HCT from an A/A donor had a fungal in-
fection density score of 0.33 compared to 0.53 for
recipients of a B/x donor (P 5 .39). The cumulative
incidence of fungal infection by day 180 in the A/A
and the B/x cohorts were 20% (95% CI, 10-34) and
25% (16-36), respectively (P 5 .57). Over one-third
of patients in each group received fluconazole for anti-
fungal prophylaxis, particularly in the initial 4 weeks
post-HCT.
When the fungal infection density was analyzed for
other potential risk factors, patients with an A/A donor
had a lower mean ratio of fungal infections at 0.62
(0.31-1.26) versus a B/x donor (P 5 .19) (Figure 3).
There were no other factors associated with altered
risks of fungal infections.All Infections
Over the study period, only 19 (16%) patients had
no infections. Of these, 15 were in the B/x cohort. Of
Table 2. Other Factors Associated with Risk of Infections
Any Infection
Variable
Relative Mean Number
of Infections (95% CI) P-Value
Donor age, years
50 and older 1.00 .05*
40-49 0.88 (0.60-1.27) .48†
30-39 0.84 (0.59-1.19) .32†
20-29 0.64 (0.45-0.91) .01†
Donor/recipient sex match .03*
Female/female 1.00
Male/male 1.25 (0.93-1.68) .13†
Female/male 1.10 (0.80-1.51) .54†
Male/female 0.80 (0.56-1.14) .21†
Donor/recipient CMV serostatus .0005*
Positive/positive 1.00
Positive/negative 0.91 (0.64-1.29) .59†
Negative/positive 1.48 (1.08-2.00) .01†
Negative/negative 0.89 (0.61-1.30) .56†
Bacterial Infections
Variable
Ratio of Mean Number
of Infections† (95% CI) P-Value
HLA match <.0001*
Well Mmtched 1.00
Partially matched 1.65 (1.22-2.23) .001†
Mismatched 2.24 (1.59-3.13) .0001†
Graft type .0007
PBSC 1.00
Marrow 0.61 (0.46-0.81)
Viral Infections
Variable
Ratio of Mean Number
of Infections† (95% CI) P-Value
Donor/recipient sex match
Female/female 1.00
Male/male 5.11 (1.78-14.42) .002†
Female/male 3.31 (1.08-9.98) .03†
Male/female 2.84 (0.90-8.80) .07†
Donor/recipient CMV serostatus
Positive/positive 1.00
Positive/negative 1.13 (0.46-2.73) .79†
Negative/positive 2.14 (1.03-4.40) .04†
Negative/negative 0.30 (0.10-0.92) .04†
CMV indicates cytomegalovirus; CI, confidence interval; PBSC, periph-
eral blood stem cell.
*P-value of overall test.
†Compared to the reference group rate 1.0
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ing (A/A 5 2; B/x 5 5), 8 received reduced intensity
conditioning (A/A 5 1; B/x 5 7), and 4 received non-
myeloablative conditioning (A/A 5 1; B/x 5 3). The
mean number of all infections was 5.39 per patient
per day at risk (Figure 1). The cumulative incidence
of any infection by day 180 posttransplant was 93%
(95% CI, 84-99) for A/A donor HCT compared to
88% (95% CI, 79-94) for a B/x donor (P5 .30).
In the adjusted infection density analysis, recipi-
ents of an A/A donor had a mean ratio of infections
of 1.14 (0.92-1.41; P 5 .23) compared to those with
a B/x donor (Figure 3). Older donor age and CMVseropositive recipients were also associated with
a higher ratio of infections.Other Transplant Outcomes
TRM did not differ by KIR genotype. Recipients
of an A/A donor compared to a B/x donor had
100-day TRM of 25% (95% CI, 12-40) versus 26%
(95% CI, 16-39; p 5 .88). The cumulative incidence
of grades II–IV acute GVHD (aGVHD) at 100 days
was also similar (A/A: 39%, 95% CI, 25-53; B/x:
32%, 95% CI, 22-43; P 5 .47). Survival at 1 year
and cGVHD were also similar between the groups.
Recipients of an A/A versus a B/x donor had a 1-year
survival of 34% (95% CI, 21-49) versus 29% (95%
CI, 19-40) and a cumulative incidence of cGVHD at
1 year of 34% (95% CI, 21-49) versus 36% (95% CI,
26-48).
In multivariate regression analysis, the donor KIR
genotype had no impact on the relative risk of aGVHD
grades II-IV, cGVHD, or 1-year survival. Only BM as
the stem cell source decreased the risk of cGVHD (rel-
ative risk [RR]: peripheral blood stem cell [PBSC] 5
1.0, BM 5 0.39; 95% CI, 0.20-0.76; P 5 .005).DISCUSSION
HCT from an unrelated donor with a B/x KIR ge-
notype resulted in a lower cumulative incidence of bac-
terial infections by 6 months posttransplant, although
analyses of specific other infectious complications
including viral, fungal, and overall infections were sim-
ilar. Furthermore, after adjusting for multiple infec-
tions and other factors including patient age, stem
cell source, disease, HLA match, and CMV serostatus,
there is a modestly but not significantly lower number
of bacterial infections using a KIR B/x unrelated
donor. The use of a KIR B/x unrelated donor had no
impact on any other transplant outcomes including
aGVHD and cGVHD, TRM, and 1-year survival in
this small cohort.
All infection data for our cohort of 116 patients
were collected prospectively during the study period
with detailed auditing and review for completeness.
We also analyzed multiple classes of infection includ-
ing bacterial, fungal, viral, and overall infectious syn-
dromes. Several other groups have reported on the
impact of NK cells and donor KIR—either KIR ligand
match status or KIR genotype—on infectious compli-
cations following allogeneic HCT [15,16,21-24]. Only
the study by Kim et al. [24] reported on multiple infec-
tious complications, including CMV reactivation,
overall infectious events, bacterial infections, viral
infections, and fungal infections. However, their study
analyzed the graft dose of NK cells infused, rather than
the KIR genotype, from 61 HLA identical sibling
1160 Biol Blood Marrow Transplant 16:1155-1161, 2010M. Tomblyn et al.donors. They observed that patients infused with.5
107 NK cells/kg had fewer bacterial infections and
fewer overall infections.
Only 2 studies have included unrelated donor
HCT and infectious complications in relation to NK
cells and KIR [15,23]. Schaffer et al. [23] reported out-
comes in 190 unrelated donor transplants who received
antithymocyte globulin. They reported a higher TRM
in patients receiving KIR ligand mismatched donor
grafts (n 5 23), apparently because of increased infec-
tious complications, but the details of the infections
were not reported. Cook et al. [12] analyzed HCT in-
fections based on the donor A/A and B/x genotype in
145 HLA identical siblings, 65 URD, and 24 haploi-
dentical donor grafts. In the subset of CMV
seropositive patients receiving a myeloablative condi-
tioning regimen and a CMV seropositive HLA identi-
cal sibling graft, they observed a decreased risk of CMV
reactivation if the donor had a KIR B/x genotype. This
differed from our data and studies by others [16,22].
In recipients of HLA identical sibling T-replete
transplants, Chen et al. [16] reported that reactivation
of CMV was similar in recipients of an A/A versus a B/x
donor. However, if the donor had a higher number of
activating KIR genes compared to the recipient, there
was a decreased risk of CMV reactivation. In 43 HLA
identical sibling transplants, Clausen et al. [22] found
no impact of the KIR genotype on CMV reactivation,
but did find higher nonrelapse mortality in recipients
with donors who had 3 or more activating KIR genes.
Taken together, these data highlight the complexity
and the uncertainties of the NK cell and KIR effect on
infectious complications following allogeneic HCT.
Based upon our cohort size and the number of infectious
events, we could not fully address how diagnosis, condi-
tioning intensity, use of T cell depletion, and HLA
matching or donor-recipient KIR ligand matching
might interact with the donor A/A versus B/x KIR geno-
type. Nonetheless, we found a lower cumulative inci-
dence of bacterial infections in recipients with a B/x
donor, although we were unable to analyze the NK
cell dose as reported by Kim et al. [24]. Although not
reaching statistical significance, it is notable that 21%
of recipients of a B/x donor had no infectious complica-
tions between day 0 and 6 months posttransplant, com-
pared to only 9% of patients receiving cells from an A/A
donor. Larger cohorts, best studied prospectively, will
be needed to analyze these infectious risks more fully.
Our findings that recipients of B/x unrelated donor
grafts have fewer bacterial infections are intriguing.
This could be because of indirect interactions between
NK cells and other components of the innate immune
system. Alternatively, a ubiquitous bacterial compo-
nent may more effectively trigger NK cells with an ac-
tivating KIR genotype. Finally, it is also possible that
the alloreactive effects of NK cells may be permissive
or facilitative for subsequent immune reconstitutionand thus further decrease the risk for later infectious
complications.
In conclusion, the role of donor KIR genotype on
the development of infections posttransplant is poten-
tially important, but may be modified by multiple fac-
tors including T cell depletion, the donor source
(related versus unrelated versus haploidentical), and
possibly, the KIR ligand match status. Analysis of
a larger cohort may more fully determine the impact
of NK cells and KIR genotype on infectious outcomes
posttransplantation.ACKNOWLEDGMENTS
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